Contact Registry for Clinical Trials
Recruiting
The purpose of the Contact Registry for Clinical Trials is to develop a database/listserv of persons interested in clinical trials occurring at the University of Central Florida College of Medicine. Sign up for the UCF College of Medicine's Contact Registry for Clinical Trials to learn about clinical research and clinical trials in areas of interest to you! https://ucf.qualtrics.com/jfe/form/SV_do4WGvKlz4f8Wwe
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Central Florida, Orlando, Florida
Conditions: This is the Contact Registry
Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Recruiting
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Multiple Myeloma
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
Recruiting
The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/22/2024
Locations: Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington
Conditions: Interaction
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +10 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC
Recruiting
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California +2 locations
Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
SIRI Checklist: An Integrated Hospital Model to Optimize HIV Prevention in Persons Who Inject Drugs
Recruiting
The purpose of this study is to develop and test a serious injection-related injections (SIRI) checklist aimed at increasing evidence-based treatment for rural people who use drugs (PWUD) including innovative, long-acting injectable agents. The central hypothesis is that hospital-based care models can successfully engage rural and Southern (PWUD) in effective addiction treatment and infection prevention. The activities in this study will be foundational to Ending the HIV epidemic in rural states... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: HIV Infections, Opioid-Related Disorders, Pre-Exposure Prophylaxis (PrEP)
Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
Recruiting
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Community Health Network, Indianapolis, Indiana +12 locations
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Recruiting
The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Altoona Center for Clinical Research, Duncansville, Pennsylvania
Conditions: Rheumatoid Arthritis (RA)
Investigating Near-Threshold Perception During Anesthetic Sedation
Recruiting
The researchers expect to gain a deeper understanding of mental function during different levels of anesthesia, and to evaluate if the use of ultrasonic brain stimulation accelerates return to consciousness. Propofol is FDA approved for use in patients undergoing an anesthetic for medical treatment but is not approved for use in healthy volunteers.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
11/06/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Propofol, Anesthesia, fMRI
A Randomized Clinical Trial of a Novel Drug Education and Diversion Program (iDECIDE) for Middle and High School Students
Recruiting
The primary goal of this study is to test the effectiveness of the iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment) curriculum, a novel drug education and diversion program, in approximately 300 middle and high school students, who have violated their school substance use policies in the past month, as an alternative to punitive school responses for school-based substance use infractions. This randomized controlled trial will test the hypothesis that adolescents rand... Read More
Gender:
ALL
Ages:
Between 9 years and 22 years
Trial Updated:
11/05/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Substance Use, Harm Reduction, Adolescent Behavior
Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients
Recruiting
Participants recruited for this study will be breast cancer or gynecological cancer patients who agree to participate in an exercise study examining the effects of chemotherapy on muscle mitochondrial oxidative capacity, a measure of skeletal muscle health. Participants will ride a stationary bicycle and the quadriceps muscle will be non-invasively evaluated.
Gender:
FEMALE
Ages:
20 years and above
Trial Updated:
11/01/2024
Locations: Prisma Health Cancer Institute, Greenville, South Carolina
Conditions: Breast Cancer, Gynecologic Cancers, Mitochondrial Function
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
Recruiting
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/01/2024
Locations: Arizona Liver Health, Chandler, Arizona +5 locations
Conditions: Hepatic Impairment, Healthy Volunteers